Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance
mSystems · 22.04.2025 · 10 (4)
DOI: 10.1128/msystems.00184-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSystems, erschienen am 22.04.2025. Verfasst von Jie Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, beta-Lactamases, Azabicyclo Compounds, Bacterial Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Program for Youth Innovation in Future Medicine of Chongqing Medical University.
Abstract (Originalsprache)
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive. To better elucidate these resistant phenotypes, we cloned 33 clinically described KPC variants (from KPC-2 to KPC-36) and 8 artificially created variants into a common plasmid vector and assessed their impact on β-lactam susceptibility. Strains expressing KPC-14, KPC-28, and KPC-31 exhibited increased resistance to ceftazidime and ceftazidime-avibactam but decreased resistance to carbapenems. We further studied the catalytic mechanism of β-lactam hydrolysis by KPC-4, KPC-14, KPC-15, KPC-16, KPC-21, KPC-25, KPC-28, KPC-31, and the ancestral KPC-2 and KPC-3 enzymes. Antimicrobial susceptibility test, enzyme kinetics, and molecular modeling revealed diverse selective pressures, including but not limited to aztreonam and ceftriaxone, driving KPC evolution, with ceftazidime playing a central role. Substitutions within the KPC hydrolytic active sites notably reduced the inhibitory effect of avibactam on KPC, demonstrated by isothermal titration calorimetry analysis, resulting in enhanced hydrolysis of ceftazidime by enzyme kinetics. This highlights that avibactam may serve as an additional driving force in KPC evolution. IMPORTANCE The rapid evolution of KPC carbapenemases, including resistance to ceftazidime-avibactam, threatens the effectiveness of last-resort antibiotics against Klebsiella pneumoniae infections, necessitating understanding of of the underlying selection pressures. This study investigates the evolutionary mechanisms driving KPC diversification and resistance to ceftazidime-avibactam, providing crucial information for developing effective strategies to combat carbapenem-resistant Klebsiella pneumoniae (CRKP) infections and preserve antibiotic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing, China.
- The Key Laboratory of Molecular Biology of Infectious Diseases designated by the Chinese Ministry of Education Chongqing Medical University, Yuzhong, Chongqing, China.
- Department of Clinical Laboratory, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, China.
- College of Laboratory Medicine, Chongqing Medical University, Yuzhong, Chongqing, China.
- Department of Clinical Laboratory, University-Town Hospital of Chongqing Medical University, Chongqing, China.
- Center for Discovery and Innovation Hackensack Meridian Health, Nutley, New Jersey, USA.
ORCID-Profile: Jie Wei, Barry N Kreiswirth, Liang Chen, Deqiang Wang, Siqiang Niu
Förderung
- NIH HHS
- NIAID NIH HHS
- Program for Youth Innovation in Future Medicine of Chongqing Medical University
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
- Xiangshan Talent Project of Zhuhai People's Hospital
- Clinical Research Promotion Project of Zhuhai Peoples's Hospital
- National Institutes of Health
Zitieren
APA
Wei, J., Huang, J., Zou, C., Shen, S., Kreiswirth, B. N., Huang, A., Huang, S., Chen, L., Wang, D., & Niu, S. (2025). Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance. mSystems, 10(4). https://doi.org/10.1128/msystems.00184-25
Vancouver
Wei J, Huang J, Zou C, Shen S, Kreiswirth BN, Huang A, et al. Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance. mSystems. 2025;10(4). doi:10.1128/msystems.00184-25
BibTeX
@article{Wei2025,
author = {Wei, Jie and Huang, Jinyu and Zou, Chunhong and Shen, Shimei and Kreiswirth, Barry N and Huang, Ailong and Huang, Shifeng and Chen, Liang and Wang, Deqiang and Niu, Siqiang},
title = {Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance},
journal = {mSystems},
year = {2025},
volume = {10},
number = {4},
doi = {10.1128/msystems.00184-25}
}
EUVIMED